Hospital
Cayuga Medical Center at Ithaca
Cayuga Medical Center at Ithaca was paid $33.24M by Medicaid between Jan 2018 and Dec 2024, across 347 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 21% of everything it billed.
33Billing provider infoCAYUGA MEDICAL CENTER AT ITHACA
ITHACA, NY 14850
ITHACA, NY 14850
33aNPI1962422733assigned 07/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.24M
24GClaims832,261
24DCodes billed347
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#41 of 231
Median peer was paid$561K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 313 | $16K | |
| 2019 | 43,856 | $1.38M | |
| 2020 | 158,157 | $5.56M | |
| 2021 | 185,127 | $6.21M | |
| 2022 | 159,722 | $8.57M | |
| 2023 | 161,624 | $7.17M | |
| 2024incomplete | 123,462 | $4.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 21% | 51,377 | 47,382 | $7.04M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12% | 60,582 | 45,931 | $4.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.4% | 12,037 | 11,314 | $2.12M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 14,561 | 6,493 | $1.44M |
| 36415 | Collection of venous blood by venipuncture | 4.0% | 31,094 | 25,340 | $1.32M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 7,629 | 7,327 | $1.31M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.2% | 4,688 | 4,021 | $1.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 7,406 | 7,000 | $1.01M |
| 80053 | Comprehensive metabolic panel | 2.1% | 42,059 | 37,736 | $700K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 851 | 847 | $698K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 2,309 | 2,219 | $669K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 2,355 | 2,308 | $567K |
335 more codes
| 99285 | Emergency room visit (most serious) | 1.5% | 3,608 | $511K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 3,822 | $507K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 8,096 | $480K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 2,178 | $404K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 5,618 | $401K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,916 | $359K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.0% | 709 | $337K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 690 | $308K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 265 | $278K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 556 | $254K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,123 | $253K |
| 97161 | <1% | 1,893 | $241K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,445 | $233K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,127 | $215K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,637 | $210K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,260 | $204K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,491 | $198K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 786 | $187K |
| 97162 | <1% | 1,136 | $173K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,603 | $163K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,447 | $157K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,429 | $155K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,855 | $137K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,261 | $135K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,335 | $125K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,946 | $118K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,062 | $112K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 241 | $111K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 362 | $109K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,782 | $107K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,366 | $106K |
| 12001 | <1% | 261 | $106K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,321 | $102K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,375 | $99K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,117 | $94K |
| 88342 | <1% | 249 | $93K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,648 | $92K |
| 76830 | Ultrasound, transvaginal | <1% | 1,749 | $90K |
| 82607 | <1% | 7,189 | $86K | |
| 80061 | Lipid panel | <1% | 13,345 | $82K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,097 | $77K |
| 86481 | <1% | 1,544 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,989 | $75K |
| 82728 | <1% | 5,804 | $73K | |
| 86780 | <1% | 5,367 | $67K | |
| 84439 | <1% | 7,705 | $66K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,465 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,497 | $64K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 969 | $62K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 128 | $60K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,373 | $50K |
| G0378 | Hospital observation service, per hour | <1% | 1,250 | $49K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23,285 | $47K |
| 93971 | <1% | 741 | $46K | |
| 86850 | <1% | 2,807 | $46K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 65 | $45K |
| 87077 | <1% | 6,918 | $44K | |
| 82746 | <1% | 3,577 | $43K | |
| 86803 | <1% | 4,355 | $41K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 166 | $38K |
| 94060 | <1% | 151 | $38K | |
| 86618 | <1% | 2,652 | $37K | |
| 86762 | <1% | 2,520 | $36K | |
| 83880 | <1% | 1,155 | $36K | |
| 87480 | <1% | 3,494 | $36K | |
| 87510 | <1% | 3,491 | $36K | |
| 84403 | <1% | 1,344 | $36K | |
| 96415 | <1% | 61 | $34K | |
| 87070 | <1% | 5,673 | $34K | |
| 73564 | <1% | 2,493 | $33K | |
| 83655 | <1% | 2,521 | $32K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,931 | $32K |
| 86901 | <1% | 2,859 | $31K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 58 | $31K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 208 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,310 | $29K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 381 | $29K |
| 86900 | <1% | 2,860 | $27K | |
| 84702 | <1% | 7,982 | $27K | |
| 86140 | <1% | 12,595 | $27K | |
| 87340 | <1% | 2,596 | $26K | |
| 0012A | <1% | 903 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,446 | $24K |
| 83540 | <1% | 5,190 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 181 | $24K |
| 72141 | <1% | 52 | $24K | |
| 86003 | <1% | 598 | $23K | |
| 93226 | <1% | 131 | $23K | |
| 0011A | <1% | 971 | $23K | |
| 95816 | <1% | 140 | $23K | |
| 83550 | <1% | 4,798 | $22K | |
| 83735 | <1% | 8,788 | $22K | |
| 88304 | <1% | 883 | $21K | |
| 76641 | <1% | 501 | $19K | |
| 82784 | <1% | 1,585 | $19K | |
| 87468 | <1% | 704 | $19K | |
| 87186 | <1% | 4,415 | $18K | |
| 87660 | <1% | 1,687 | $18K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $18K |
| 0001A | <1% | 708 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,852 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 448 | $17K |
| 85610 | <1% | 7,533 | $17K | |
| 84146 | <1% | 832 | $16K | |
| 73630 | <1% | 2,272 | $16K | |
| 82670 | <1% | 512 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 166 | $16K |
| 51798 | <1% | 46 | $16K | |
| 86376 | <1% | 1,065 | $15K | |
| 76536 | <1% | 515 | $15K | |
| 86665 | <1% | 569 | $15K | |
| 87469 | <1% | 704 | $15K | |
| 87484 | <1% | 704 | $15K | |
| 85027 | <1% | 4,764 | $15K | |
| 87478 | <1% | 700 | $15K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 19 | $14K |
| 87640 | <1% | 240 | $14K | |
| 83001 | <1% | 739 | $14K | |
| 83970 | <1% | 336 | $14K | |
| 73030 | <1% | 1,707 | $14K | |
| 73610 | <1% | 2,455 | $14K | |
| 82947 | <1% | 4,132 | $13K | |
| 80076 | <1% | 1,687 | $13K | |
| 90715 | <1% | 465 | $13K | |
| 76000 | <1% | 91 | $13K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 424 | $13K |
| 73110 | <1% | 1,860 | $13K | |
| 73130 | <1% | 1,778 | $13K | |
| 64721 | <1% | 14 | $12K | |
| 86706 | <1% | 1,265 | $11K | |
| 82570 | <1% | 2,240 | $11K | |
| 84481 | <1% | 1,228 | $11K | |
| 85652 | <1% | 5,881 | $10K | |
| 72110 | <1% | 562 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 42 | $10K |
| 97803 | <1% | 388 | $10K | |
| 36591 | <1% | 267 | $10K | |
| 95886 | <1% | 67 | $10K | |
| 81001 | <1% | 6,908 | $9K | |
| 83002 | <1% | 471 | $9K | |
| 73502 | <1% | 990 | $9K | |
| 82043 | <1% | 1,697 | $8K | |
| 86617 | <1% | 450 | $8K | |
| 70486 | <1% | 102 | $8K | |
| 87481 | <1% | 327 | $8K | |
| 96367 | <1% | 291 | $7K | |
| 86787 | <1% | 727 | $7K | |
| 86038 | <1% | 1,425 | $7K | |
| 83525 | <1% | 619 | $7K | |
| 76775 | <1% | 120 | $7K | |
| 86769 | <1% | 256 | $7K | |
| 95806 | <1% | 276 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 144 | $7K |
| 86664 | <1% | 544 | $7K | |
| 74018 | <1% | 974 | $7K | |
| 87641 | <1% | 325 | $7K | |
| 81003 | <1% | 8,942 | $6K | |
| 12002 | <1% | 13 | $6K | |
| 86431 | <1% | 1,260 | $6K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 490 | $6K |
| 86704 | <1% | 631 | $6K | |
| 86708 | <1% | 629 | $6K | |
| 72100 | <1% | 678 | $6K | |
| 76642 | <1% | 219 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,113 | $6K |
| 12011 | <1% | 15 | $6K | |
| 86765 | <1% | 423 | $6K | |
| 82550 | <1% | 1,823 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,973 | $5K |
| 71271 | <1% | 132 | $5K | |
| 10060 | <1% | 15 | $5K | |
| 86364 | <1% | 631 | $5K | |
| 82533 | <1% | 285 | $5K | |
| 87205 | <1% | 2,407 | $5K | |
| 77062 | <1% | 173 | $5K | |
| 83690 | <1% | 4,256 | $4K | |
| 73221 | <1% | 12 | $4K | |
| 73140 | <1% | 1,153 | $4K | |
| 85730 | <1% | 1,691 | $4K | |
| 84425 | <1% | 276 | $4K | |
| 97802 | <1% | 153 | $4K | |
| 84550 | <1% | 981 | $4K | |
| 70496 | <1% | 12 | $4K | |
| 73080 | <1% | 583 | $4K | |
| 94726 | <1% | 54 | $3K | |
| 71250 | <1% | 41 | $3K | |
| 84100 | <1% | 941 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 63 | $3K |
| 86039 | <1% | 651 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 2,181 | $3K |
| 87634 | <1% | 422 | $3K | |
| 83921 | <1% | 153 | $3K | |
| 86800 | <1% | 234 | $3K | |
| 86696 | <1% | 228 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 233 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $3K |
| 86747 | <1% | 84 | $3K | |
| 87040 | <1% | 1,606 | $3K | |
| 84156 | <1% | 753 | $3K | |
| 87563 | <1% | 121 | $3K | |
| 84402 | <1% | 101 | $2K | |
| 86235 | <1% | 121 | $2K | |
| 72040 | <1% | 239 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 257 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 51 | $2K |
| 82105 | <1% | 327 | $2K | |
| 99156 | <1% | 863 | $2K | |
| 36592 | <1% | 100 | $2K | |
| 85379 | <1% | 1,302 | $2K | |
| 84480 | <1% | 354 | $2K | |
| 80178 | <1% | 348 | $2K | |
| 0002A | <1% | 69 | $2K | |
| 0031A | <1% | 47 | $2K | |
| 76870 | <1% | 54 | $2K | |
| 84484 | <1% | 6,579 | $2K | |
| 94729 | <1% | 54 | $2K | |
| 84590 | <1% | 143 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 24 | $2K |
| 70498 | <1% | 25 | $2K | |
| 72131 | <1% | 12 | $1K | |
| 86735 | <1% | 171 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,422 | $1K |
| 86141 | <1% | 161 | $1K | |
| 81596 | <1% | 25 | $1K | |
| 95911 | <1% | 25 | $1K | |
| 87328 | <1% | 106 | $1K | |
| 83605 | <1% | 5,512 | $1K | |
| 84446 | <1% | 97 | $1K | |
| 86160 | <1% | 72 | $1K | |
| 82248 | <1% | 329 | $1K | |
| 73590 | <1% | 230 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,002 | $1K |
| 86308 | <1% | 439 | $1K | |
| 87329 | <1% | 93 | $1K | |
| 84165 | <1% | 161 | $1K | |
| 84460 | <1% | 223 | $1K | |
| 76801 | <1% | 17 | $987.23 | |
| 83993 | <1% | 86 | $956.76 | |
| 88173 | <1% | 51 | $920.74 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $855.23 |
| 90686 | <1% | 32 | $832.01 | |
| 86777 | <1% | 52 | $827.32 | |
| 84144 | <1% | 37 | $811.96 | |
| 84436 | <1% | 365 | $805.26 | |
| 72070 | <1% | 85 | $797.40 | |
| 87899 | <1% | 69 | $781.80 | |
| 82150 | <1% | 214 | $767.30 | |
| 73560 | <1% | 183 | $748.96 | |
| 86778 | <1% | 51 | $720.12 | |
| 87045 | <1% | 92 | $654.55 | |
| 84155 | <1% | 134 | $590.62 | |
| 82040 | <1% | 128 | $569.61 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 36 | $566.72 |
| 83615 | <1% | 183 | $550.60 | |
| 84479 | <1% | 660 | $535.26 | |
| G0008 | Administration of influenza virus vaccine | <1% | 43 | $529.20 |
| 86225 | <1% | 95 | $487.00 | |
| 80164 | <1% | 60 | $452.38 | |
| 73090 | <1% | 123 | $423.76 | |
| 73523 | <1% | 25 | $371.12 | |
| 76882 | <1% | 64 | $361.66 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,015 | $342.41 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,552 | $334.76 |
| 82977 | <1% | 66 | $323.56 | |
| 96376 | <1% | 1,008 | $318.15 | |
| 87046 | <1% | 92 | $293.54 | |
| 81025 | <1% | 79 | $245.63 | |
| 86036 | <1% | 16 | $233.60 | |
| 86592 | <1% | 69 | $199.47 | |
| 82525 | <1% | 12 | $183.84 | |
| 93000 | <1% | 128 | $166.65 | |
| 85014 | <1% | 93 | $166.37 | |
| 82247 | <1% | 40 | $160.87 | |
| 73620 | <1% | 27 | $155.81 | |
| 72050 | <1% | 12 | $140.00 | |
| 85018 | <1% | 78 | $137.13 | |
| 99152 | <1% | 623 | $136.62 | |
| 80175 | <1% | 13 | $126.00 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 323 | $125.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,827 | $123.30 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 446 | $121.60 |
| 81513 | <1% | 17 | $113.85 | |
| 84630 | <1% | 14 | $110.60 | |
| 87177 | <1% | 12 | $106.80 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 799 | $99.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,723 | $93.16 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,867 | $90.65 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 15 | $87.85 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,242 | $82.72 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 929 | $79.14 |
| 84482 | <1% | 13 | $74.10 | |
| 87209 | <1% | 12 | $70.92 | |
| 71101 | <1% | 12 | $70.36 | |
| 87102 | <1% | 13 | $58.87 | |
| 86255 | <1% | 12 | $57.20 | |
| 83630 | <1% | 12 | $57.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,983 | $56.88 |
| 82565 | <1% | 12 | $55.33 | |
| J3490 | Unclassified drugs | <1% | 279 | $54.20 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,194 | $52.87 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,834 | $44.89 |
| 82274 | <1% | 14 | $41.16 | |
| 82803 | <1% | 45 | $32.40 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,005 | $26.28 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,521 | $26.22 |
| J1240 | Injection, dimenhydrinate, up to 50 mg | <1% | 179 | $25.61 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 60 | $24.00 |
| 85046 | <1% | 13 | $22.86 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 53 | $12.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 531 | $10.57 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 26 | $8.95 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 250 | $8.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 882 | $7.92 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 663 | $3.88 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 72 | $1.27 |
| 91301 | <1% | 55 | $0.14 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 102 | $0.00 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 0% | 102 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| 88311 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 17 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 144 | $0.00 |
| 99157 | 0% | 663 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 134 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 506 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| 81002 | 0% | 64 | $0.00 | |
| G8731 | Pain assessment using a standardized tool is documented as negative, no follow-up plan required | 0% | 66 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 18 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 15 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 56 | $0.00 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 0% | 13 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 20 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOULD, REBECCA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Cayuga Medical Center at Ithaca | Ithaca, NY | $111K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.